Company Profile
Our business focus is on the discovery and development of drugs that modulate mitochondrial function in cancer, diabetes, cardiovascular diseases and neurodegenerative diseases.
We are building on an existing drug pipeline which consists of drugs which combine the actions of apoptosis inducers and angiogenesis inhibitors for use in the treatment of a wide range of solid and blood-borne cancers.
We are the only company in the World with a unique range of High Throughput Screening (HTS) assays and other contract research services for the measurement of mitochondrial function, and we can provide you with a competitive edge.
We are based at BioCity Nottingham, a state-of-the-art bioincubator in the heart of the city of Nottingham, England, U.K.
Our latest research has shown that cannabinoids can work directly through the inhibition of mitochondrial function, and can induce apoptotic cell death in human lung cancer cells.